AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3562198 — intervention group
Group type: EXPERIMENTAL
Intervention: Precued hand condition
Number of subjects: 60
Study 3562198 — intervention group
Group type: EXPERIMENTAL
Intervention: Precued direction condition
Number of subjects: 60
Study 3562198 — intervention group
Group type: EXPERIMENTAL
Intervention: Precued midline condition
Number of subjects: 60
Study 3562198 — intervention group
Group type: COMPARATOR
Intervention: Normal group (control)
Number of subjects: 60
Study 31775146 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) applied weekly for 6 months on 1 eye
Number of subjects: 105
Study 29492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 0
Study 27319363 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional round stool
Number of subjects: 4
Study 27319363 — intervention group
Group type: EXPERIMENTAL
Intervention: Round stool with backrest
Number of subjects: 4
Study 27319363 — intervention group
Group type: EXPERIMENTAL
Intervention: Saddle chair with backrest
Number of subjects: 4
Study 27319363 — intervention group
Group type: EXPERIMENTAL
Intervention: Capisco chair
Number of subjects: 4
Study 24954936 — intervention group
Group type: COMPARATOR
Intervention: Classroom delivery
Number of subjects: 0
Study 24954936 — intervention group
Group type: COMPARATOR
Intervention: Online delivery
Number of subjects: 0
Study 22869834 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, family-centered behavioral intervention (Salud Con La Familia program) consisting of 12 weekly 90-minute sessions
Number of subjects: 106
Study 22869834 — intervention group
Group type: COMPARATOR
Intervention: Alternative school-readiness program
Number of subjects: 106
Study 20163347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-nicotinate 400 microg/day for 16 weeks
Number of subjects: 52
Study 20163347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18474395 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day)
Number of subjects: 10
Study 18474395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15699832 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin/tobramycin alone (n = 130)
Number of subjects: 515
Study 15699832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin/chlorhexidine alone (n = 130)
Number of subjects: 515
Study 15699832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (n = 129)
Number of subjects: 515
Study 15699832 — intervention group
Group type: COMPARATOR
Intervention: All placebos (n = 126)
Number of subjects: 515
Study 12577162 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine group (n=21; induction with 0.5 mg/kg BW esketamine and 1.5 mg/kg BW methohexitone)
Number of subjects: 64
Study 12577162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane group (n=21; induction with 1.5-2.0 mg/kg BW methohexitone)
Number of subjects: 64
Study 12577162 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia group (n=22; 2.6-3.0 ml isobaric bupivacaine 0.5%)
Number of subjects: 64
Study 10495859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate 5 mg (group A)
Number of subjects: 30
Study 10495859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 30
Study 8904748 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa 100 mg with benserazide 25 mg
Number of subjects: 31
Study 8904748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1809401 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 19
Study 1809401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus antacids as needed (prn)
Number of subjects: 18
Study 7140494 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prn antacids
Number of subjects: 18
Study 31690765 — intervention group
Group type: EXPERIMENTAL
Intervention: Putrescine
Number of subjects: 3
Study 31690765 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine
Number of subjects: 3
Study 31690765 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermine
Number of subjects: 3
Study 31690765 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamine concentration of 1 mM
Number of subjects: 3
Study 31690765 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamine concentration of 4 mM
Number of subjects: 3
Study 31690765 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamine treatments
Number of subjects: 3
Study 29806090 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with golimumab
Number of subjects: 60
Study 26712960 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour quit attempt (blacks)
Number of subjects: 6813
Study 26712960 — intervention group
Group type: COMPARATOR
Intervention: 24-hour quit attempt (whites)
Number of subjects: 6813
Study 26712960 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day quit attempt (blacks)
Number of subjects: 6813
Study 26712960 — intervention group
Group type: COMPARATOR
Intervention: 7-day quit attempt (whites)
Number of subjects: 6813
Study 26712960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month continuous abstinence (blacks)
Number of subjects: 6813
Study 26712960 — intervention group
Group type: COMPARATOR
Intervention: 6-month continuous abstinence (whites)
Number of subjects: 6813
Study 26712960 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of 6-month continuous abstinence
Number of subjects: 6813
Study 24184853 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT) application in the FAI group
Number of subjects: 28
Study 24184853 — intervention group
Group type: COMPARATOR
Intervention: No tape application in the control group
Number of subjects: 28
Study 22027945 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA) 10 mg/day for 14 days
Number of subjects: 38
Study 19278832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne device
Number of subjects: 46
Study 19278832 — intervention group
Group type: COMPARATOR
Intervention: Tooth-borne device
Number of subjects: 46
Study 17404897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of Coherence (SOC)
Number of subjects: 107
Study 17404897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental symptoms (measured by the Symptom Checklist‐90 revised)
Number of subjects: 107
Study 15081451 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug sedation (group 1)
Number of subjects: 46
Study 15081451 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic sedation (group 2)
Number of subjects: 46
Study 11701427 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE (acetate infusion with 4 mmol/kg body wt sodium acetate)
Number of subjects: 8
Study 11701427 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP (hyperoxia breathing 100% O(2))
Number of subjects: 8
Study 11701427 — intervention group
Group type: COMPARATOR
Intervention: CON (saline infusion while breathing room air)
Number of subjects: 8
Study 9751587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 20
Study 9751587 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic intermittent positive airway pressure ventilation (BIPAP)
Number of subjects: 20
Study 7831451 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (high-dose 3 mg/kg/day)
Number of subjects: 0
Study 7831451 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (medium-dose 1.5 mg/kg/day)
Number of subjects: 0
Study 7831451 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (low-dose 0.5 mg/kg/day)
Number of subjects: 0
Study 7831451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2458035 — intervention group
Group type: EXPERIMENTAL
Intervention: Human surfactant treatment
Number of subjects: 46
Study 2458035 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 2458035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (human surfactant and control)
Number of subjects: 46
Study 29459986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 to 400 mg) for 12 months
Number of subjects: 248
Study 29459986 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 248
Study 29459986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 to 400 mg)
Number of subjects: 248
Study 29459986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 27054571 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRNA4 SNPs (specifically rs1044396 and rs1044397)
Number of subjects: 1705
Study 27054571 — intervention group
Group type: EXPERIMENTAL
Intervention: N100 amplitude reduction
Number of subjects: 1705
Study 25330500 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label DES use (n=1,033)
Number of subjects: 1387
Study 25330500 — intervention group
Group type: COMPARATOR
Intervention: On-label DES use (n=354)
Number of subjects: 1387
Study 23772804 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity + weight loss (PA + WL)
Number of subjects: 288
Study 23772804 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA)
Number of subjects: 288
Study 23772804 — intervention group
Group type: COMPARATOR
Intervention: Successful aging (SA) health education
Number of subjects: 288
Study 21955429 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI)
Number of subjects: 1000
Study 21955429 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 1000
Study 18556139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alcohol (.04%)
Number of subjects: 161
Study 18556139 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (.08%)
Number of subjects: 161
Study 18556139 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 161
Study 18556139 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 161
Study 16622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice (Blend‐a‐Med Complete Night)
Number of subjects: 29
Study 16622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice plus tongue brushing
Number of subjects: 29
Study 16622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice
Number of subjects: 29
Study 16622641 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (Crest Cavity Protection)
Number of subjects: 29
Study 12748864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 34
Study 12748864 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 34
Study 12748864 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-L (Legs)
Number of subjects: 34
Study 12748864 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-O (Overall)
Number of subjects: 34
Study 12748864 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-C (Breathing/Chest)
Number of subjects: 34
Study 10673523 — intervention group
Group type: COMPARATOR
Intervention: White children
Number of subjects: 518
Study 10673523 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American (AA) children
Number of subjects: 518
Study 10673523 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish surname (SS) children
Number of subjects: 518
Study 8879097 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (1440 EL.U.)
Number of subjects: 110
Study 8879097 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccine plus YF vaccine
Number of subjects: 110
Study 8879097 — intervention group
Group type: COMPARATOR
Intervention: YF vaccine
Number of subjects: 110
Study 1513960 — intervention group
Group type: EXPERIMENTAL
Intervention: Model plus verbal rehearsal
Number of subjects: 60
Study 1513960 — intervention group
Group type: COMPARATOR
Intervention: Verbal rehearsal only
Number of subjects: 60
Study 1513960 — intervention group
Group type: COMPARATOR
Intervention: Model only
Number of subjects: 60
Study 6434422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with carbohydrate application adjusted to O2-consumption
Number of subjects: 40
Study 6434422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with various infusion regimens
Number of subjects: 40
Study 6434422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with increased amino-acid intake
Number of subjects: 40
Study 6434422 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced delivery of energy-yielding substrates
Number of subjects: 40
Study 6434422 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-methylhistidine excretion in urine
Number of subjects: 40
Study 30677485 — intervention group
Group type: EXPERIMENTAL
Intervention: MyHEART intervention (multi‐component, theoretically‐based program for hypertension self-management)
Number of subjects: 310
Study 30677485 — intervention group
Group type: EXPERIMENTAL
Intervention: MyHEART intervention
Number of subjects: 310
Study 29543891 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Game (SG) intervention
Number of subjects: 73
Study 26481177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant programming for 12 weeks postoperatively or after tinnitus occurrence
Number of subjects: 234
Study 26481177 — intervention group
Group type: COMPARATOR
Intervention: Control subgroup
Number of subjects: 234
Study 24976987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (individualized education and telephone counseling for 6 months)
Number of subjects: 0
Study 24976987 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22189066 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 45
Study 22189066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21059444 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day
Number of subjects: 112
Study 21059444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 18043428 — intervention group
Group type: COMPARATOR
Intervention: Surgical implantation of an investigational epidural electrode over the posterior superior temporal gyrus with functional magnetic resonance imaging targeting, followed by a 2-week stimulation period alternating with a 2-week sham period, and then continuous stimulation.
Number of subjects: 8
Study 18043428 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chronic stimulation of the secondary auditory cortex.
Number of subjects: 8
Study 15833901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus behavior feedback with biased scanning
Number of subjects: 0
Study 15833901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus behavior feedback with consideration of undesirable outcomes
Number of subjects: 0
Study 15833901 — intervention group
Group type: EXPERIMENTAL
Intervention: Different behavioral paradigm and field study
Number of subjects: 0
Study 12523876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 729
Study 12523876 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 729
Study 9820261 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized acupuncture regimen (SAR)
Number of subjects: 250
Study 9820261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/d)
Number of subjects: 250
Study 9820261 — intervention group
Group type: COMPARATOR
Intervention: Control points (for acupuncture comparison)
Number of subjects: 250
Study 9820261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for amitriptyline comparison)
Number of subjects: 250
Study 7674695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study 7674695 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG coenzyme‐A reductase inhibitors
Number of subjects: 0
Study 2620672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg
Number of subjects: 99
Study 2620672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 99
Study 98801 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 22
Study 98801 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 22
Study 29632254 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP 0-3
Number of subjects: 0
Study 29632254 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP 3-5
Number of subjects: 0
Study 29632254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined VIP 0-3 and VIP 3-5
Number of subjects: 0
Study 29632254 — intervention group
Group type: COMPARATOR
Intervention: Control 0-3 years
Number of subjects: 0
Study 29632254 — intervention group
Group type: COMPARATOR
Intervention: Control 3-5 years
Number of subjects: 0
Study 28448397 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pentazocine (15 mg, 1 mL)
Number of subjects: 119
Study 28448397 — intervention group
Group type: COMPARATOR
Intervention: IV saline (1 mL)
Number of subjects: 119
Study 25743386 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically-qualified doctors with early breast cancer
Number of subjects: 276
Study 25743386 — intervention group
Group type: COMPARATOR
Intervention: Matched control patients with early breast cancer
Number of subjects: 276
Study 23438351 — intervention group
Group type: EXPERIMENTAL
Intervention: Early visit to a doctor
Number of subjects: 173
Study 23438351 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 173
Study 20940647 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonist/Antagonist (AA) training group
Number of subjects: 24
Study 20940647 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternated Strength Training (AST) group
Number of subjects: 24
Study 20940647 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 18787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention consisting of group sessions focused on recollecting specific events and personal identity exercises.
Number of subjects: 0
Study 18787361 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 16801509 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted standard-dose warfarin sodium
Number of subjects: 17833
Study 16801509 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted low-dose warfarin
Number of subjects: 17833
Study 16801509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 17833
Study 16801509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 17833
Study 16801509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17833
Study 14585520 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot 2.5 cm²
Number of subjects: 0
Study 14585520 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot 3.75 cm²
Number of subjects: 0
Study 14585520 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot 5.0 cm²
Number of subjects: 0
Study 14585520 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot 10.0 cm²
Number of subjects: 0
Study 14585520 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot (all doses)
Number of subjects: 0
Study 10903016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 120
Study 10903016 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium omitted
Number of subjects: 120
Study 10903016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.45 mg kg(‐1)
Number of subjects: 120
Study 10903016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg(‐1)
Number of subjects: 120
Study 10903016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg(‐1) followed by neostigmine 40 microg kg(‐1) and atropine 20 microg kg(‐1)
Number of subjects: 120
Study 8923336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 7
Study 8923336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1560167 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional plus 22 minutes of interactive computer‐assisted instruction
Number of subjects: 52
Study 1560167 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruction (counseling and written instruction)
Number of subjects: 52
Study 6371225 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 36
Study 6371225 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 36
Study 6371225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30621828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate to high risk for OSA (modified STOP‐BANG score ≥ 3)
Number of subjects: 222
Study 30621828 — intervention group
Group type: COMPARATOR
Intervention: Low risk for OSA (score < 3)
Number of subjects: 222
Study 29194899 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reimbursement
Number of subjects: 746
Study 29194899 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support
Number of subjects: 746
Study 29194899 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT-C screening tool
Number of subjects: 746
Study 27064456 — intervention group
Group type: EXPERIMENTAL
Intervention: $800 reward contingent on sustained abstinence from smoking
Number of subjects: 2538
Study 27064456 — intervention group
Group type: EXPERIMENTAL
Intervention: $150 refundable deposit plus a $650 reward
Number of subjects: 2538
Study 27064456 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2538
Study 24462505 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H-MRS) and transcranial magnetic stimulation (TMS) in concussed athletes
Number of subjects: 30
Study 24462505 — intervention group
Group type: COMPARATOR
Intervention: Proton magnetic resonance spectroscopy (1H-MRS) and transcranial magnetic stimulation (TMS) in control athletes
Number of subjects: 30
Study 22540996 — intervention group
Group type: EXPERIMENTAL
Intervention: CEL-100 videolaryngoscope
Number of subjects: 170